Business Wire

TANNER-PHARMA-GROUP

24.3.2022 13:03:10 CET | Business Wire | Press release

Share
Tanner Pharma Increases Europe-Based Inventory of Leukine® to Expand Availability and Enhance Response to Potential Radiation Exposure Due to the Ongoing Conflict in Ukraine

Tanner Pharma Group , an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine (sargramostim, yeast-derived rhuGM-CSF) to be held in Europe. This action is being taken in partnership with Leukine’s owner, Partner Therapeutics (PTx), in response to the ongoing war in Ukraine and escalating potential for incidents that could require rapid deployment of medical interventions to treat radiation or chemical exposure.

“In response to the ongoing conflict in Ukraine, Tanner is supporting preparedness and response in Europe by increasing the local inventory of Leukine that can be rapidly deployed in response to an emergency,” said Banks Bourne, CEO and Founder of Tanner Pharma. “The unique efficacy of Leukine, which has been shown to improve survival when given within 96 hours after radiation exposure and without whole blood transfusions, makes it a highly effective countermeasure with important logistical advantages in the event of a nuclear detonation. Positioning more supply in Europe ensures that more Leukine is available quickly, if needed.”

Leukine is an immune system modulator that is FDA approved to treat the hematopoietic effects of acute radiation syndrome and has been held for use by the U.S. Government as a medical countermeasure since 2013. Leukine is also recommended to treat H-ARS in the International Atomic Energy Association (IAEA) 2020 Medical Management of Radiation Injuries(1) and was used to successfully treat some victims of the Chernobyl Nuclear Power Plant in 1986.(2) Beyond ARS, Leukine is recommended in EMEA/CPMP Guidance Document on the Use of Medicinal Products for the Treatment of Patients Exposed to Terrorist Attacks with Chemical Agents as a treatment for exposure to sulfur mustard (HD) gas.(3) It is currently under development, but not currently FDA-approved for use against sulfur mustard exposure.

High doses of radiation profoundly damage the body’s immune system. Damaged cells include monocytes, macrophages, platelets, neutrophils, dendritic cells and red blood cells, in other words, pancytopenia. Leukine stimulates each of these cell types and is shown to accelerate recovery from pancytopenia. Its broad impact enables increased survival from ARS without the need for blood transfusions. This is a critical advantage given the expectation that after a radiological or nuclear event, blood products will be limited or unavailable. It is also the only ARS countermeasure that has been shown to be effective when administered more than 24 hours after exposure. In fact, the studies have shown efficacy when administered up to 96 hours after exposure. (4,5) In the aftermath of radiological or nuclear event, a 48-96 hour treatment window is absolutely critical. (6,7) The logistical challenges of making supplies and health care professionals available for response and treatment suggest it will be 2 days before drugs can be administered at any scale. Leukine is also stable at room temperature for 12 months, eliminating the need for a refrigerated supply chain in a crisis.

Below is a summary of the use of Leukine for Acute Radiation Syndrome (ARS) and Sulfur Mustard (HD) Gas Exposure provided by Partner Therapeutics:

ABOUT LEUKINE IN ACUTE RADIATION SYNDROME (ARS)

Leukine is FDA approved to increase survival in patients exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome or H-ARS). Data from multiple GLP NHP studies funded by the U.S. Biomedical Advanced Research and Development Authority (BARDA) demonstrate that Leukine increases survival by stimulating thrombopoiesis and significantly increasing platelet count in addition to accelerating the recovery of leukocytes and reticulocytes, thereby addressing all three primary components of hematopoietic damage from radiation exposure, collectively pancytopenia. NHP studies show that Leukine improves survival and accelerates recovery from myelosuppression (including thrombocytopenia) when given up to 96 hours post radiation exposure. (4,5,8) Leukine is not EMA approved for H-ARS.

Leukine is a yeast-derived recombinant form of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), a pleiotropic small protein that promotes the generation of megakaryocytic and erythroid progenitors and induces progenitor cells to divide and differentiate within the granulocyte and macrophage pathways. Leukine induces production, maturation and differentiation of the myeloid lineages of hematopoietic precursor cells, including granulocyte, macrophage, platelet, dendritic cell and red cell lineages. It also activates mature granulocytes and monocytes, increasing their phagocytic and lytic properties. Leukine’s impact on platelets, monocytes, macrophages, and dendritic cells, in addition to its known effects on neutrophils, has been shown across several disease states and supports its use in H-ARS.

Leukine’s FDA label in ARS reads: “To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome [H-ARS]);” Leukine® for Injection: see www.leukine.com/pi for Leukine prescribing information.

ABOUT LEUKINE IN SULFUR MUSTARD (HD) GAS EXPOSURE

Leukine is not FDA or EMA approved to treat HD gas exposure. Leukine is recommended in EMEA/CPMP Guidance Document on the Use of Medicinal Products for the Treatment of Patients Exposed to Terrorist Attacks with Chemical Agents as a treatment for exposure to HD gas.

HD exposure suppresses bone marrow function, leading to myelosuppression and pancytopenia. Leukopenia was reported in patients requiring hospitalization after exposure during WWI, WWII and the Iran-Iraq War, and mortality was reported in all cases where leukocyte counts dropped below 200/µl6 . While mortality is reported in less than 2.5% of all exposed to HD, hematological damage is the primary driver of hospitalization and severe hematological damage is the primary cause of mortality. (10)

Leukine accelerates recovery of bone marrow function and recovery from pancytopenia and decreases deaths from infections in persons with bone marrow failure under diverse circumstances including following intensive chemotherapy and after acute high-dose whole body radiation in the context of hematopoietic cell transplants.(4,5,8) Both clinical experience in persons receiving Leukine after chemotherapy and therapeutic radiation and data from GLP NHP ARS studies supporting Leukine’s approval and use in those indications, demonstrate that Leukine accelerates recovery from bone marrow suppression and pancytopenia and reduces the rate of infection and septicemia, and is likely to provide the same benefit after HD exposure. (4-5,9-11)

Tanner provides a regulatory-compliant pathway to make Leukine available in international markets. For more information about this program or to request access to Leukine, please email leukine@tannerpharma.com .

ABOUT TANNER PHARMA GROUP

Tanner Pharma Group partners with biopharmaceutical companies to provide turn-key solutions that increase patient access to medicines around the world. Expanding across 130+ countries, Tanner provides tailored solutions to biopharmaceutical companies outside their core markets of focus. For more information, visit www.tannerpharma.com .

For more information about Partner Therapeutics, visit https://www.partnertx.com/ .

(1) Medical management of radiation injuries, Vienna, International Atomic Energy Agency, 2020; Safety Reports Series no. 101.

(2) Dainiak N, Medical management of acute radiation syndrome and associated infections in a high-casualty incident, Journal of Radiation Research, Vol. 59, No. S2, 2018, p. ii54-ii64. Doi:10.1093/jrr/rry004

(3) EMEA/CPMP Guidance Document on the Use of Medicinal Products for the Treatment of Patients Exposed to Terrorist Attacks with Chemical Agents; The European Agency for the Evaluation of Medicinal Products Pre-authorisation Evaluation of Medicines for Human Use, London, 25 April 2003; EMEA/CPMP/1255/03

(4) Clayton N, et al. (2021): Sargramostim (rhu GM-CSF) Improves Survival of Non-Human Primates with Severe Bone Marrow Suppression after Acute, High-Dose, Whole-Body Irradiation, Radiation Research 195:191-199. https://doi.org/10.1667/RADE-20-00131.1

(5) Zhong Y, et al. (2020): Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a non-human primate total body irradiation model, Int. J. Radiat. Biol.; https://doi.org/10.1080/09553002.2019.1673499

(6) Yeddanapudi N, et. al., (2018): Informing CONOPS and medical countermeasure deployment strategies after an improvised nuclear device detonation: the importance of delayed treatment efficacy; Int. J. Radiat. Biol.

(7) Pray L, et al., (2019): Exploring Medical and Public Health Preparedness for a Nuclear Incident: Proceedings of a Workshop; National Academies Press. http://doi.org/10.17226/25372

(8) Gale R, Armitage J, (2021): Use of molecularly cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations; Blood Reviews 45; https://doi.org/10.1016/j.blre.2020.100690

(9) Leukine Package Insert

(10) Willems, JL, Clinical management of mustard gas casualties, Ann Med Milit Belg 1989; 3: S1-61.

(11) Sezigan S, et. al., Myelosuppression and acute hematological complications of sulfur mustard exposure in victims of chemical terrorism, Toxicology Letters 318 (2020) 92-98.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release

Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release

Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye